Moderna, Inc.
CAMBRIDGE, MA / ACCESSWIRE / August 23, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission (EC) has granted marketing authorization for mRESVIA® (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. The marketing authorization follows the Positive Opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP). The authorization is valid in all 27 EU member states, as well as Iceland, Liechtenstein and Norway.
"The European Commission's approval of mRESVIA is an important milestone for public health and highlights Moderna's mRNA leadership. This approval marks the first time an mRNA vaccine has been approved for a disease beyond COVID-19 in Europe," said Stéphane Bancel, Chief Executive Officer of Moderna. "mRESVIA safeguards older adults against severe RSV outcomes and is uniquely offered in a pre-filled syringe to enhance ease of administration, which can reduce vaccine preparation time and administrative errors."
RSV is a highly contagious seasonal respiratory virus and a leading cause of lower respiratory tract infections and pneumonia. It causes a particularly high burden of disease in infants and older adults. In the European Union, RSV is estimated to cause approximately 160,000 hospital admissions in adults each year, with 92% of these admissions occurring in adults aged 65 and over.1
The marketing authorization for mRESVIA is based on positive data from the Phase 3 clinical trial ConquerRSV, a global study conducted in approximately 37,000 adults ages 60 years or older in 22 countries. The primary analysis with 3.7 months of median follow-up found a vaccine efficacy (VE) against RSV lower respiratory tract disease (LRTD) of 83.7% (95.88% CI 66.0%, 92.2%), with these results published in The New England Journal of Medicine. In a supplementary analysis with 8.6 months of median follow-up, mRNA-1345 maintained durable efficacy, with sustained VE of 63.3% (95% CI: 48.7%, 73.7%) against RSV-LRTD, including two or more symptoms. VE was 74.6% (95% CI, 50.7, 86.9) against RSV-LRTD with ≥2 symptoms, including shortness of breath, and VE was 63.0% (95% CI, 37.3%, 78.2%) against RSV LRTD including three or more symptoms. The stringent statistical criterion of the study, a lower bound on the 95% CI of >20%, continued to be met for both endpoints. The most commonly reported solicited adverse reactions were injection site pain, fatigue, headache, myalgia and arthralgia.
In May 2024, the U.S. Food and Drug Administration (FDA) approved mRESVIA (mRNA-1345) to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. The approval was granted under a breakthrough therapy designation and marked Moderna's second approved mRNA product. Moderna has filed for mRNA-1345 marketing authorization applications in multiple markets worldwide.
About mRESVIA® (Respiratory Syncytial Virus Vaccine)
mRESVIA® is an RSV vaccine that consists of an mRNA sequence encoding a stabilized prefusion F glycoprotein. The F glycoprotein is expressed on the surface of the virus and is required for infection by helping the virus to enter host cells. The prefusion conformation of the F protein is a significant target of potent neutralizing antibodies and is highly conserved across both RSV-A and RSV-B subtypes. The vaccine uses the same lipid nanoparticles (LNPs) as the Moderna COVID-19 vaccines.
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the authorization by the European Commission of Moderna's RSV vaccine mRESVIA; the vaccine efficacy and safety of mRNA-1345; the potential for mRESVIA to reduce disease burden from RSV; and Moderna's pending marketing authorization applications for mRNA-1345. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.
Moderna Contacts
Media:
Luke Mircea-Willats
Senior Director, International Communications
Luke.mirceawillats@modernatx.com
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com
1Osei-Yeboah R, Spreeuwenberg P, Del Riccio M, Fischer TK, Egeskov-Cavling AM, Bøås H, van Boven M, Wang X, Lehtonen T, Bangert M, Campbell H, Paget J; Respiratory Syncytial Virus Consortium in Europe (RESCEU) Investigators. Estimation of the Number of Respiratory Syncytial Virus-Associated Hospitalizations in Adults in the European Union. J Infect Dis. 2023 Nov 28;228(11):1539-1548. doi: 10.1093/infdis/jiad189. PMID: 37246742; PMCID: PMC10681866.
SOURCE: Moderna, Inc.
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Shaping Tomorrow: Empowering Women Today - Celebrating International Women's Day 2025 and Advancing Equality for All7.3.2025 01:30:00 CET | Press release
Empowering Women and Girls for a Sustainable Future OTTAWA, ON / ACCESS Newswire / March 7, 2025 / On International Women's Day 2025, the Almas Jiwani Foundation joins global efforts to recognize the remarkable contributions of women and girls worldwide while acknowledging the critical work still required to achieve gender equality. "The empowerment of women and girls is fundamental to achieving a just and peaceful world. As we work toward the Sustainable Development Goals, we must ensure that gender equality is not just an aspiration, but a central tenet of global cooperation. True progress can only be achieved when women and girls are given the rights, opportunities, and platforms to lead, innovate, and contribute to the solutions that will shape our collective future. The United Nations must continue to champion these values, ensuring that the voices of all women are heard, and their potential fully realized in every corner of the globe." - The Honorable Bob Rae, Canadian Ambassador
Amnesty International Adopts Preserve365 to Streamline the Archiving and Preservation of Human Rights Records in Microsoft 3656.3.2025 09:00:00 CET | Press release
BOSTON, MA AND OXFORD, UK / ACCESS Newswire / March 6, 2025 / Preservica, a pioneer in Active Digital Preservation archiving, is proud to announce that Amnesty International has selected Preserve365® to enhance archiving and preservation for its critical human rights records. The global organization, dedicated to researching, advocating, and mobilizing to end human rights abuses, will use Preservica's embedded Active Digital Preservation solution for Microsoft 365 to transform how it archives records in Microsoft SharePoint. Using Preservica's Enterprise software, Amnesty International has already built an extensive digital archive spanning over 60 years of documentation on human rights abuses and the work of the organisation. Without a modern preservation solution, decades of human rights records faced significant risks due to file corruption, outdated formats and change or deletion. By adopting Preserve365, Amnesty International can now standardize and automate the archiving of files
World of Coffee Geneva 2025 to Showcase 450+ Specialty Coffee Brands, Innovations, and Cutting-Edge Technology June 26-286.3.2025 03:00:00 CET | Press release
A Must-Attend Event Bringing Together 13,000 Coffee Professionals, Enthusiasts, and Innovators from Around the Globe GENEVA, SWITZERLAND / ACCESS Newswire / March 6, 2025 / World of Coffee Geneva 2025 marks the final opportunity for companies to exhibit at a Specialty Coffee Association (SCA) trade show in the 2024-2025 cycle, following the wildly successful World of Coffee Dubai, Specialty Coffee Expo (sold out show floor) and World of Coffee Jakarta (sold out show floor). This highly anticipated event will welcome 13,000 international coffee professionals from every part of the specialty coffee value chain, from producers to C-suite executives of large, multinational companies to the Palexpo SA in Geneva, Switzerland, from June 26-28, 2025. "World of Coffee Europe is thriving in a period of remarkable growth, with increasing attendance and a growing number of exhibitors and sponsors recognizing the immense value of in-person engagement," said Yannis Apostolopoulos, CEO of the Special
Fintech Sandbox Announces Global Startups Presenting at Demo Day 115.3.2025 09:00:00 CET | Press release
Nonprofit's Demo Day Showcases Startups Shaping the Future of Finance BOSTON, MA / ACCESS Newswire / March 5, 2025 / Today, Fintech Sandbox, a nonprofit that provides early-stage fintech startups around the world with free access to critical datasets and infrastructure through its Data Access Residency, unveiled the lineup of global startups for Demo Day 11. This free, virtual event will take place on April 28, and is being presented during UK Fintech Week for the first time. It will feature five pioneering startups demonstrating solutions developed during their tenure as residents. Fintech Sandbox's Data Access Residency fuels the next wave of fintech innovation by providing startups with free access to critical datasets and resources. This year, visionary founders, investors, and industry leaders will converge to explore breakthrough advancements in insurtech, climate tech, supply chain analytics, banking solutions, financial inclusion, and retail trading strategies. "As we approach
IXOPAY Launches Payment Account Reference Solution, Deepening Customer Insights in Digital Commerce5.3.2025 00:00:00 CET | Press release
PAR provides a single, non-sensitive identifier that connects all transactions tied to a payment account LEHI, UT / ACCESS Newswire / March 5, 2025 / IXOPAY, a leading provider of enterprise-grade payment orchestration, today announced the launch of its Payment Account Reference (PAR) solution, enabling merchants and payment platforms to link transaction data across multiple payment channels and methods. This gives marketing and customer-facing teams unprecedented visibility into purchasing behavior across payment methods, making PAR a powerful tool for delivering the personalized shopping experiences consumers expect. Until now, connecting customer purchases across an ever-increasing number of payment methods has been difficult or impossible for many merchants. IXOPAY's PAR solution, based on the system first developed by EMVCo, restores this visibility, helping merchants build stronger relationships and deliver more personalized experiences-without compromising security. Just as a fa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom